Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Primary sclerosing cholangitis: A review and update.

Tabibian JH, Bowlus CL.

Liver Res. 2017 Dec;1(4):221-230. doi: 10.1016/j.livres.2017.12.002.

PMID:
29977644
2.

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Bahar R, Wong KA, Liu CH, Bowlus CL.

Gastroenterol Hepatol (N Y). 2018 Mar;14(3):154-163.

3.

A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.

Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW.

Hepatol Commun. 2018 Mar 23;2(5):484-491. doi: 10.1002/hep4.1173. eCollection 2018 May.

4.

Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.

Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL.

Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30409-9. doi: 10.1016/j.cgh.2018.04.047. [Epub ahead of print]

PMID:
29705262
5.

Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment.

Lu M, Zhou Y, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, Anderson H, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Bowlus CL, Lindor K, Zhang T, Trudeau S, Li J, Rupp LB, Gordon SC; Fibrotic Liver Disease Consortium Investigators.

Clin Gastroenterol Hepatol. 2017 Dec 23. pii: S1542-3565(17)31529-X. doi: 10.1016/j.cgh.2017.12.033. [Epub ahead of print]

PMID:
29277621
6.

The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.

Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F.

Clin Rev Allergy Immunol. 2018 Apr;54(2):282-294. doi: 10.1007/s12016-017-8655-y.

PMID:
29256057
7.

Scratching the surface of cholestatic itch treatments.

Bowlus CL.

Hepatology. 2018 May;67(5):2045-2048. doi: 10.1002/hep.29698. Epub 2018 Apr 1. No abstract available.

PMID:
29194716
8.

Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.

Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, Safer R, Lenderking WR, Skalicky A, Kleinman L, Myers RP, Subramanian GM, McHutchison JG, Levy C, Bowlus CL, Kowdley K, Muir AJ.

Hepatology. 2018 Jul;68(1):155-165. doi: 10.1002/hep.29664. Epub 2018 May 10.

PMID:
29152767
9.

Evaluation of indeterminate biliary strictures.

Bowlus CL, Olson KA, Gershwin ME.

Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):749. doi: 10.1038/nrgastro.2017.154. Epub 2017 Nov 2.

PMID:
29094722
10.

Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems.

Lu M, Li J, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, Raebel MA, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Bowlus CL, Lindor K, Rupp LB, Gordon SC; FOLD Investigators.

Clin Gastroenterol Hepatol. 2017 Oct 21. pii: S1542-3565(17)31243-0. doi: 10.1016/j.cgh.2017.10.018. [Epub ahead of print]

PMID:
29066370
11.

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.

PMID:
28818518
12.

Common Variable Immunodeficiency and Liver Involvement.

Song J, Lleo A, Yang GX, Zhang W, Bowlus CL, Gershwin ME, Leung PSC.

Clin Rev Allergy Immunol. 2017 Aug 7. doi: 10.1007/s12016-017-8638-z. [Epub ahead of print] Review.

PMID:
28785926
13.

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrumpf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK.

Gut. 2018 Aug;67(8):1517-1524. doi: 10.1136/gutjnl-2016-313598. Epub 2017 Aug 4.

PMID:
28779025
14.

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

Henriksen EKK, Viken MK, Wittig M, Holm K, Folseraas T, Mucha S, Melum E, Hov JR, Lazaridis KN, Juran BD, Chazouillères O, Färkkilä M, Gotthardt DN, Invernizzi P, Carbone M, Hirschfield GM, Rushbrook SM, Goode E; UK-PSC Consortium, Ponsioen CY, Weersma RK, Eksteen B, Yimam KK, Gordon SC, Goldberg D, Yu L, Bowlus CL, Franke A, Lie BA, Karlsen TH.

HLA. 2017 Oct;90(4):228-233. doi: 10.1111/tan.13076. Epub 2017 Jul 11.

PMID:
28695657
15.

Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics.

Tanaka T, Zhang W, Sun Y, Shuai Z, Chida AS, Kenny TP, Yang GX, Sanz I, Ansari A, Bowlus CL, Ippolito GC, Coppel RL, Okazaki K, He XS, Leung PSC, Gershwin ME.

Hepatology. 2017 Sep;66(3):885-895. doi: 10.1002/hep.29245. Epub 2017 Jul 20.

PMID:
28470667
16.

Human β-Defensin 2 in Primary Sclerosing Cholangitis.

Chang C, Lleo A, Kananurak A, Grizzi F, Tsuneyama K, Invernizzi P, Bevins CL, Bowlus CL.

Clin Transl Gastroenterol. 2017 Mar 16;8(3):e80. doi: 10.1038/ctg.2017.8.

17.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group.

Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

18.

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR.

Haemophilia. 2017 Mar;23(2):198-206. doi: 10.1111/hae.13178. Epub 2017 Jan 25.

PMID:
28124511
19.

The evolution of natural history of primary sclerosing cholangitis.

Takakura WR, Tabibian JH, Bowlus CL.

Curr Opin Gastroenterol. 2017 Mar;33(2):71-77. doi: 10.1097/MOG.0000000000000333. Review.

20.

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.

Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller TJ, Gotthardt DN, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma RK, Wijmenga C, Marschall HU, Milkiewicz P, Pares A, Kontula K, Chazouillères O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Floreani A, Gulamhusein AF, Eaton JE, Schreiber S, Coltescu C, Bowlus CL, Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, Sandford RN, Alexander G, Gaffney DJ, Chapman RW, Hirschfield GM, de Andrade M; UK-PSC Consortium; International IBD Genetics Consortium; International PSC Study Group, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Anderson CA.

Nat Genet. 2017 Feb;49(2):269-273. doi: 10.1038/ng.3745. Epub 2016 Dec 19.

Supplemental Content

Loading ...
Support Center